Alphatec (NASDAQ:ATEC) Shares Gap Down – Should You Sell?

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) gapped down before the market opened on Wednesday . The stock had previously closed at $13.93, but opened at $13.26. Alphatec shares last traded at $13.6060, with a volume of 1,452,764 shares traded.

Alphatec News Roundup

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Q4 revenue and growth: Alphatec reported revenue up ~20.4% year‑over‑year to about $212.9M, showing solid top‑line momentum and improved gross profit. This supports the company’s growth story. Zacks: ATEC Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Analyst support: Several firms reaffirmed Buy ratings (Needham, H.C. Wainwright) and set mid-$20s price targets, which may underpin buy‑side interest after the print. TipRanks: Needham reiterates Buy
• Neutral Sentiment: Profitability & cash flow trends: Management highlighted stronger profitability and a target of 17% revenue growth for 2026 while improving cash flow — positive longer‑term but depends on execution. Seeking Alpha: 17% growth target
• Neutral Sentiment: Mixed messaging on EPS: Different sources report different EPS figures (some outlets cite a small EPS beat on an adjusted basis; others report a GAAP diluted loss of about $0.14), creating investor confusion about the true earnings beat/miss. See call transcripts and presentation for detail. Seeking Alpha: Earnings call transcript
• Negative Sentiment: 2026 revenue guidance below some expectations: Several outlets flagged that the company’s 2026 revenue guide/assumptions were below street estimates, which appears to be the primary negative catalyst for the intraday sell‑off. Investing.com: Falls on guidance below estimates
• Negative Sentiment: Large insider/institutional selling highlighted by some data providers — plenty of reported insider sales in recent periods, which can weigh on sentiment even as institutions add positions. Quiver Quant: Stock falls on Q4 results and insider activity

Analysts Set New Price Targets

A number of analysts have recently commented on the company. TD Cowen reissued a “buy” rating on shares of Alphatec in a research note on Tuesday, January 27th. Loop Capital set a $25.00 target price on shares of Alphatec in a research report on Wednesday, December 10th. Wall Street Zen raised shares of Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, January 31st. Piper Sandler reaffirmed an “overweight” rating on shares of Alphatec in a research note on Wednesday. Finally, Morgan Stanley set a $23.00 price objective on shares of Alphatec in a research note on Tuesday, December 2nd. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.82.

Alphatec Trading Down 2.8%

The company has a debt-to-equity ratio of 43.02, a current ratio of 1.99 and a quick ratio of 1.24. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -13.02 and a beta of 1.01. The firm’s fifty day moving average is $17.09 and its 200-day moving average is $17.15.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $212.93 million during the quarter, compared to the consensus estimate of $212.67 million. During the same period last year, the business posted ($0.23) earnings per share. The business’s revenue was up 20.4% on a year-over-year basis. Equities analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Insider Transactions at Alphatec

In other Alphatec news, EVP David Sponsel sold 60,425 shares of Alphatec stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $13.79, for a total value of $833,260.75. Following the completion of the sale, the executive vice president directly owned 349,500 shares of the company’s stock, valued at approximately $4,819,605. The trade was a 14.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David R. Pelizzon sold 250,000 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $19.66, for a total transaction of $4,915,000.00. Following the transaction, the director directly owned 10,395,045 shares in the company, valued at $204,366,584.70. This trade represents a 2.35% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 1,436,125 shares of company stock valued at $29,385,878. 22.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd bought a new position in Alphatec in the third quarter worth approximately $34,000. Osterweis Capital Management Inc. bought a new position in shares of Alphatec in the 2nd quarter worth $37,000. Northwestern Mutual Wealth Management Co. grew its position in Alphatec by 157.1% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company’s stock valued at $54,000 after purchasing an additional 1,571 shares during the period. Nisa Investment Advisors LLC increased its stake in Alphatec by 22.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after purchasing an additional 1,045 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Alphatec during the third quarter worth $73,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.